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S-Glutathionylationofcysteineresidueswithintargetproteinsisaposttranslationalmodiﬁcationthataltersstructureandfunction.
We have shown that S-glutathionylation of protein disulﬁde isomerase (PDI) disrupts protein folding and leads to the activation
of the unfolded protein response (UPR). PDI is a molecular chaperone for estrogen receptor alpha (ERα). Our present data show
in breast cancer cells that S-glutathionylation of PDI interferes with its chaperone activity and abolishes its capacity to form
ac o m p l e xw i t hE R α. Such drug treatment also reverses estradiol-induced upregulation of c-Myc, cyclinD1, and P21Cip,g e n e
products involved in cell proliferation. Expression of an S-glutathionylation refractory PDI mutant diminishes the toxic eﬀects of
PABA/NO. Thus, redox regulation of PDI causes its S-glutathionylation, thereby mediating cell death through activation of the
UPR and abrogation of ERα stability and signaling.
1.Introduction
Glutathione S-transferase pi (GSTP) is a biomarker protein
in drug-resistant solid epithelial tumors, including ovarian,
breast, liver, pancreatic, lung, and lymphoma [1]. In some
cases, GSTP can be the most abundant protein in the tumor
and, consequently, has the potential to serve as an important
drug target [2–4]. One therapeutic approach has been to
develop prodrugs that are substrates for GSTP and become
cytotoxic when liberated in cancer cells, yet exhibit dimin-
ished activation/toxicity in normal tissue. PABA/NO (O2-
[2,4-dinitro-5-[4-(N-methylamino) benzoyloxy]phenyl] 1-
(N,N-dimethylamino) diazen-1-ium-1,2-diolate) [5]i sa
GSTP-activated prodrug that releases high levels of nitric
oxide (NO) at physiological pH. This reaction results in
the formation of a Meisenheimer-complex intermediate and
subsequently the leaving group of the reaction generates two
molecules of NO. Elevated NO levels lead to cytotoxic eﬀects
by forming RNS/ROS intermediates that can alter protein
function directly through posttranslational modiﬁcations on
redox sensitive cysteine residues (S-nitrosylation, P-SNO or
S-glutathionylation, P-SSG) [3, 6].
Prior studies have shown that protein disulﬁde isomerase
(PDI) is a molecular target of PABA/NO treatment in
cancer cells [2, 5, 7–9]. PDI is the most abundant chap-
erone/isomerase in the endoplasmic reticulum and plays
a pivotal role in protein folding through isomerase and
chaperone activity. The active site cysteine residues are S-
glutathionylated (PDI-SSG) following PABA/NO treatment.
The functional consequences are reduced isomerase activity,
accumulationofunfolded/misfoldedproteins,andactivation
of the unfolded protein response (UPR). At least one
mechanism of action for PABA/NO can be attributed to
UPR-induced cell death.
PDI shares homology with the estrogen-binding domain
of the estrogen receptor alpha (ERα)[ 10]. Despite the KDEL
sequence present in the C-terminus that retains PDI in the
endoplasmic reticulum (ER), PDI is also found in non-
ER locations [11]. With immune-aﬃnity, steroid-aﬃnity
and site-speciﬁc DNA-aﬃnity chromatography, Landel et al.
have found that in extracts from MCF-7 cells and ERα-
expressing CHO (CHO-ERα)c e l l sE R α forms complexes
with PDI, Hsp70, and two unidentiﬁed proteins [12].
Moreover, PDI enhances the binding of puriﬁed ERα to2 International Journal of Cell Biology
the estrogen response element (ERE) in a dose-dependent
manner, suggesting that this accessory protein may be
required for optimal interactions of ERα with EREs [12, 13].
Interestingly, PDI does not interact with estrogen receptor β
(ERβ)[ 10]. The DNA-binding domain and Hinge domain
of ERα are the minimal structures suﬃcient for PDI-
ERα interactions [13]. However, information regarding the
corresponding domain(s) of PDI involved in this interaction
is not presently available. The presence of estrogen neither
is required for PDI-ERα interaction [13] nor has any eﬀect
on the stoichiometry of PDI association with ERα [12]. The
PDI-ERα interaction may protect ERα from oxidation and
alter ERα conformation so that the susceptibility of ERα to
diﬀerent proteases is altered [13].
The present study evaluates the eﬃcacy of PABA/NO
in ERα-positive breast cancer cells and interrogates the
impact of S-glutathionylation of PDI on its chaperone
activity, speciﬁcally with ERα. We hypothesize that S-
glutathionylation of PDI not only blunts protein folding
but also prevents protein interaction with ERα, destabilizing
the receptor and subsequent ERα signaling (see scheme in
Figure 1).
2.MaterialandMethods
2.1. Reagents. Reduced glutathione (GSH), oxidized glu-
tathione (GSSG), and the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) reagent, and
β-estradiol were purchased from Sigma (St. Louis, MO).
Antibodies were purchased from the following sources:
anti-PDI (Aﬃnity BioReagents); anti-glutathionylation
(Virogen), anti-actin (Abcam), anti-FLAG (Sigma), anti-
ERα/anti-ERβ (Millipore), and anti-c-Myc/anti-Cyclin
D1/anti-p21 (Cell Signaling). PABA/NO (O2-[2,4-dinitro-
5-[4-(N-methylamino) benzoyloxy] phenyl]1-(N,N-
dimethylamino) diazen-1-ium-1,2-diolate) was provided by
Dr. Larry Keefer, Chemistry Section, Laboratory of Com-
parative Carcinogenesis, NCI at Frederick (MD).
2.2. Expression and Puriﬁcation of His-Tagged Recombinant
PDIs. His-tagged recombinant human PDI in the bacterial
expression vector pET-28b was provided by Dr. Lana Lee
(UniversityofWindsor,Ontario)andexpressedaspreviously
described [8, 9]. The His-tagged PDI mutant FLFL was syn-
thesizedusingtheQuikChangeSite-DirectedMutagenesiskit
(Stratagene), in which histidine 55 and 399 were changed
to phenylalanines, and lysine 57 and 401 were changed to
leucines,simultaneously.AllmutationswereveriﬁedbyDNA
sequencing.
Puriﬁed plasmids were transformed into Escherichia coli
BL21(DE3)pLysS strain, which were then induced with
1mM IPTG at 37 ◦C for 3h and pelleted at 6000rpm
for 15min at 4◦C. Cells were lysed by sonication in
lysis buﬀer (20mM NaH2PO4, 500mM NaCl). The lysates
were centrifuged at 13,000rpm for 30min at 4◦C and the
pellets were discarded. The supernatants were incubated
with Ni-NTA agarose beads (QIAGEN) for 1h at 4◦C. The
beads were washed three times with wash buﬀer (20mM
NaH2PO4, 500mM NaCl, and 10mM imidazole). His-PDIs
were eluted with elution buﬀer (20mM NaH2PO4, 500mM
NaCl, and 250mM imidazole). The eluates were dialyzed
against dialysis buﬀer (25mM HEPES, pH7.3, 100mM
N a C l ,1 m ME D T A ,a n d1 m MD T T ) .P r o t e i np u r i t yw a s
assessed on Coomassie-stained gels. Protein concentrations
were determined using the Bradford reagent with BSA as a
standard.
2.3. Expression of FLAG-Tagged PDIs in Mammalian Cells.
Full-length human PDI was ampliﬁed from a cDNA
prepared from HL60 cells using the following primers:
5 -GACGGATCCATGCTGCGCCGCGCTCTGCTG-3 and
5 -GTCGAATTCTTACAGTTCATCTTTCACAGC-3 .T h e
resulting PCR fragment was cloned into the BamHI/EcoRI
sites of pCDNA3 vector for mammalian expression. A FLAG
tagsequenceDYKDDDDK wasinsertedbetweenaminoacids
E497andD498,upstreamoftheKDELsequence[15].FLAG-
tagged PDI mutant FLFL was also generated using site-
directed mutagenesis. All mutations were veriﬁed by DNA
sequencing.
The human breast cancerline MCF7 was purchased from
the American Type Culture Collection and grown as recom-
mended by the supplier. Cells were maintained in αMEM
containing 10% FCS, 100μg/mL streptomycin, 100units/mL
penicillin, and 2mmol/L l-glutamine at 37◦Ci na5 %C O 2
incubator.ExpressionplasmidscontainingFLAG-taggedPDI
and FLFL mutant were transfected into MCF7 cells using
GenJet reagent according the manufacturer’s instruction.
Cells (2 × 106 per treatment group) were plated 24h before
drug treatment.
2.4. Fluorescent Imaging of Native and PDI Expression Vectors.
To validate that overexpression of PDI (PDI-OE) does not
lead to altered localization, transfected MCF7 cells (vector
or PDI) were seeded onto LabTek II Chamber Slides and
allowed to adhere overnight. Cells were rinsed 2X with PBS
and ﬁxed with 4% paraformaldehyde for 30min. followed
by permeabilization in 0.2% Triton X-100 in PBS. Nuclear
staining was detected using 4 ,6-diamidino-2-phenylindole
(DAPI). Nonspeciﬁc protein binding was blocked using 1%
bovine serum albumin (BSA) for 30min. Cells were then
incubated for 1h in primary anti-PDI (vector) or anti-FLAG
(PDI-OE) antibody in PBS. Unbound primary antibody was
removed by rinsing the cells 3X with PBS containing 0.05%
Tween-20. The cells were incubated with Oregon Green
secondary antibody. Following removal of the secondary
antibody, the cells were imaged by ﬂuorescent microscopy
(Nikon eclipse E800, Nikon Instr., In. Lewisville, TX using
Nikon DS-U1 software v. 5.03, Photometrics, Tucson, AZ).
2.5. Protein Preparation. Cells were harvested and washed
with phosphate-buﬀered saline (PBS). Cell pellets were
suspended in lysis buﬀer (20mM Tris-HCl, pH 7.5, 15mM
NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 2.5mM
sodium pyrophosphate, and 1mM β-glycerophosphate with
freshly added protease and phosphatase inhibitors, 5mM
NaF and 1 mM Na3VO4) and incubated for 30min onInternational Journal of Cell Biology 3
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Figure 1: Model of the chaperone activity of PDI with ERα. S-Glutathionylation of PDI can interfere with protein folding, prevent protein
interaction with ERα, and plausibly destabilize the receptor and subsequent ERα signaling.
ice. Lysates were sonicated for 10sec and centrifuged for
30min at 10,000g at 4◦C. Protein concentrations in the
supernatant were assayed with the Bradford reagent (Bio-
Rad Laboratories, Hercules, CA) using IgG as a standard.
2.6. Immunoblot Analysis. Equivalent amounts of protein
were electrophoretically resolved under nonreducing con-
ditions on 10% SDS-polyacrylamide gels (SDS-PAGE);
unmodiﬁed proteins were separated under reducing condi-
tions. Proteins were transferred onto nitrocellulose mem-
branes (Bio-Rad, Hercules, CA). Nonspeciﬁc binding was
reduced by incubating the membrane in blocking buﬀer
(20mM Tris-HCl, pH 7.5, 150mM NaCl, 0.1% Tween 20,
1μM protease inhibitors, 5mM NaF, and 1mM Na3VO4)
containing 10% nonfat dried milk for 1h. Membranes were
incubated with the indicated antibody (blocking buﬀer con-
taining5%nonfatdriedmilk)atstateddilutionsovernightat
4◦C, washed 3x with PBS for 15min, and incubated with the
appropriate secondary antibody conjugated to horseradish
peroxidase for 1h. The membranes were washed 3 times
and developed with enhanced chemiluminescence detection
reagents (Bio-Rad). The blots were scanned with a BioRad
ChemiDoc system and visualized with a transilluminator.
The images stored in a TIFF format. The relative intensity of
bands was evaluated using Quantity One software (ver. 4.5.2;
Bio-Rad) and plotted as arbitrary units (a.u.) in relation to
actin.
2.7. Spectroscopic Analysis of PDI In Vitro. The structure of
the S-glutathionylation refractory mutant (PDI-FLFL) was
evaluated and compared to the wild type (PDI-WT) by pro-
tein tryptophan ﬂuorescence scanning [8, 16]. The scan was
recorded on an F 2500 spectroﬂuorometer (Hitachi) using
10×10×40mm quartz cuvette, excitation and emission slits
were 2.5 and 5.0nm, respectively. The excitation wavelength
was 295nm to minimize an eﬀect of protein tyrosines and
phenylalanines. Background spectra were subtracted from
ﬁnal emission of the protein. Quenching experiments were
performed as follows: 1μM of PDI-WT or PDI-FLFL in
20mM PB, pH = 7.4 was titrated with 0–5000nM CsCl at
room temperature under constant stirring. The Trp emission
spectra (Ex. = 295nm) were recorded and integrated us-
ing Felix32 standard software (PTI, NJ). All data were
normalized to the emission proteins prior to addition of
CsCl. Data represent the mean ± SD for 3 independent
experiments.
2.8. PDI Activity Assay. The enzyme activities of PDI-WT
and PDI-FLFL were monitored using the turbidimetric
assay of insulin disulphide reduction [17]. Brieﬂy, 0.25μM
puriﬁed human PDI was added to a solution of insulin
(0–250μM) and GSH (500μM) in a 0.1M K2HPO4 buﬀer
containing 2mM EDTA (pH 7.0). DTT has been shown
to completely reduce the disulﬁde bonds and is used as a
positive control. The increase in turbidity was monitored
(λ = 630) at 30s intervals for 30min. Mean values and S.E.
were computed for each group, N = 3.
2.9. Cytotoxicity Assays. 10,000 cells were seeded in 96-well
plates in 50μL medium. Increasing drug concentrations of
PABA/NO were added to a ﬁnal volume of 100μLa n d
maintained in drug for 72h. Following drug exposure, cell
viabilitywasassayedbythe3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) conversion assay [14].
Each drug concentration was represented in quadruplicate
and three independent experiments were conducted. Mean
values and S.E. were computed for each group.
2.10. Statistical Analysis. Experimental data presented rep-
resent the mean value ± SD for at least three independent
experiments. Data were analyzed for statistically signiﬁcant4 International Journal of Cell Biology
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Figure 2: PABA/NO-induced S-glutathionylation of PDI in vitro. (a) MCF7 cells were seeded in a 96-well plate and treated with 0–50μM
PABA/NO. Cell viability was measured at 72h with the MTT assay [14]. Data represent the mean for 3 independent experiments ± S.D. (b)
MCF7 cells were treated with DMSO or PABA/NO at the indicated concentrations for 2h. (c) MCF7 cells were treated with DMSO or 20μM
PABA/NO for the indicated times. Cell lysates (40μg) were separated and under nonreducing conditions and subjected to Western blot with
anti-S-glutathionylation (P-SSG) and antiactin antibodies.
diﬀerences between groups with Student’s t-test using Sig-
maStat 3.5 (Systat Software Inc., San Jose, CA). Diﬀerences
were considered statistically signiﬁcant if the P value was
<0.05.
3. Results
3.1. S-Glutathionylation of PDI Disrupts the ERα-PDI Com-
plex and Stability. Prior studies have shown that PABA/NO
induces dose-dependent cell death that is concurrent with
S-glutathionylation and activation of the UPR in ovarian
and leukemia cancer cells [8]. Using MCF7 cells, we
conﬁrmed the presence of a dose- (Figure 2(a))a n dt i m e -
dependent inverse relationship of P-SSG relative to cell death
(Figure 2). Under nonstressed conditions, PDI coimmuno-
precipitates with ERα, Figure 3(a). However, PABA/NO-
induced nitrosative stress-induced S-glutathionylation of
PDI abrogates the interaction within 30min following drug
treatment (Figures 3(b) and 3(c)).
3.2. PDI Levels Aﬀect Drug-Induced ERα Proteasomal Degra-
dation. Chaperone functions of PDI are considered to be
protective of ERα when exposed to either oxidative or
nitrosative damage [13]. In fact, protein levels of ERα were
diminished 81 ± 2% following treatment with PABA/NO
(Figure 4(a)). To determine if ERα levels were decreased
as a consequence of proteosomal degradation, MCF7 cells
were pretreated with proteosomal inhibitors (MG132 andInternational Journal of Cell Biology 5
PDI
IgG
IgG
IgG
IP:
ERα
ERα
(a)
P-SSG
PDI
IP: PDI
0 0.5 2 (h)
(b)
PDI
0 0.5 2 (h)
ERα
IP: ERα
(c)
Figure 3: PABA/NO abrogates PDI-ERα interaction. (a) MCF7 cell lysates (1mg) were incubated with anti-ERα antibody or control
IgG at 4◦C overnight. (b) MCF7 cells were treated with DMSO or 20μM PABA/NO for the indicated times. Cell lysates (300μg) were
incubated with anti-PDI antibody at room temperature for 4h. The precipitated endogenous PDI was subjected to Western blot with anti-
S-glutathionylation (P-SSG) and anti-PDI antibodies. (c) MCF7 cells were treated with DMSO or 20μM PABA/NO for the indicated times.
Endogenous ERα was precipitated with the anti-ERα antibody at 4◦C overnight. The precipitates were subjected to Western blot with anti-
ERα and anti-PDI antibodies.
PS341) prior to subsequent PABA/NO exposures. Proteoso-
mal inhibition blunted PABA/NO-induced ERα degradation
(Figure 4(c)). To validate that PDI levels are critical to ERα
stability, MCF7 cells were transfected with empty vector
or with recombinant PDI to generate overexpressing cells.
Figure 5(a) shows ﬂuorescent images conﬁrming that the
sub-cellular localization of transfected, overexpressed PDI
(right panel) is consistent with native PDI (left panel). Com-
parative analysis of vector or PDI-transfected cells treated
with PABA/NO (Figure 5(b)) suggested that overexpression
of PDI stabilized intracellular ERα levels.
3.3. PDI-SSG Alters ERα-Mediated Gene Expression. Previ-
ous studies have shown that estrogen stimulation can lead to
activation of a range of proteins involved in cell proliferation
[10]. We evaluated a cadre of such response proteins
following β-estradiol ± PABA/NO treatments (Figure 6).
PABA/NO treatment appeared to counteract the expected
estrogenic eﬀects, leading to downregulation of c-Myc,
Cyclin D1, and p21. Such data are consistent with the
antiproliferative and growth arrest eﬀects of PABA/NO.
3.4. S-Glutathionylation Refractory Mutant PDI Decreased
PABA/NO-Induced Toxicity. S-glutathionylation invariably
occurs at cysteine residues found in a motif that exists in a
low pKa environment [3]. Using site-directed mutagenesis
we generated an S-glutathionylation refractory mutant,
transfected it into host cells (PDI-FLFL), and evaluated
its secondary and tertiary structure compared to PDI
and PDI-SSG [8, 9]. S-Glutathionylation altered both the
CD spectra and tryptophanyl ﬂuorescence of native PDI.
The trypophanyl ﬂuorescence scans of PDI-WT and PDI-
FLFL have overlapping spectra (P<0.05), indicating the
proteinsarefoldedsimilarly(Figure 7(a)).Furthervalidation
that protein folding of PDI-FLFL was equivalent to PDI-
WT was based upon the data showing quenching of the
protein Trp ﬂuorescence with CsCl (Figure 7(b)). There
was no statistical diﬀerence between the PDI-WT protein6 International Journal of Cell Biology
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Figure 4: PABA/NO leads to ERα proteasomal degradation. (a) MCF7 cells were treated with DMSO or 20μM PABA/NO for the indicated
times. Cell lysates (40μg) were subjected to Western blot with the indicated antibodies. (b) MCF7 cells were treated with DMSO or 20μM
PABA/NO for the indicated times. (c) MCF7 cells were pretreated with proteasome inhibitors MG132 (1μM) or PS341 (10μM) for 2h and
then treated with 20μM PABA/NO for 6h. Cell lysates (40μg) were subjected to Western blot with the indicated antibodies. Bar diagram
showed the means and standard deviations determined from three independent experiments.
and the S-glutathionylation refractory mutant (P<0.05).
Measurement of isomerase activity showed PDI and PDI-
FLFL were essentially equivalent (Figure 7(c)). Recombinant
proteinswereincubatedwithPABA/NOandGSHfor30min.
PDI was S-glutathionylated in a dose-dependent manner,
however PDI-FLFL was refractory (Figure 7(d)). PDI-WT
and PDI-FLFL were transfected into MCF7 cells and treated
with PABA/NO to induce S-glutathionylation and activate
UPR-induced cell death. Following immunoprecipitation,
PDI-WT was S-glutathionylated as detected by Western blot
analysis.However,PDI-FLFLwasnotmodiﬁed(Figure 7(e)).
S-Glutathionylation of PDI is the trigger for ERα-PDI com-
plex disruption and activation of the UPR. Consequently,
the toxic eﬀects of PABA/NO were diminished in MCF7 cells
transfected with the S-glutathionylation-resistant mutant,
PDI-FLFL (Figure 7(f)).
4. Discussion
ERα signaling is a contributing factor in the regulation of
breast cancer cell proliferation. Targeting ERα signaling is
an important and successful treatment strategy for most
breast cancer patients that are ERα positive. In the preclinical
evaluation of PABA/NO, PDI was identiﬁed as a molecular
target of the drug [2, 5, 8, 18–20]. Speciﬁcally, PDI is S-
glutathionylated on cysteine residues within the catalyticInternational Journal of Cell Biology 7
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Figure 5: PDI expression levels aﬀect PABA/NO-stimulated ERα degradation. (a) shows ﬂuorescent images detailing similar subcellular
distribution of PDI in normal and transfected cells. (b) shows Western blots of vector or PDI-transfected cells treated with PABA/NO
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MCF7cellsweretreatedwithDMSO,20nMβ-estradiol(E2),20μM
PABA/NO or both for the indicated times. Cell lysates (40μg) were
subjected to Western blot with the indicated antibodies.
domains following nitrosative stress, thereby blunting iso-
merase activity [8, 9]. PDI has homology with the estrogen-
binding domain of ERα and acts as a molecular chaperone
that is required for ERα-mediated gene regulation [21]. In
the present study we evaluated whether S-glutathionylation
of PDI also impacts chaperone function. Our data suggest
that S-glutathionylation of PDI leads to disruption of the
PDI:ERαcomplex,proteosomaldegradationoftranscription
factor, and diminished ERα mediated gene regulation.
PDI is organized into ﬁve domains (a, b, b ,a  , and c).
There are two active sites in the catalytic domains a and
a , each having two conserved cysteine residues that cycle
between oxidized (disulﬁde) and reduced (dithiol) states to
facilitate the folding and correct disulﬁde bond formation
of its protein substrates [22] .T h ec r y s t a ls t r u c t u r eo fy e a s t
PDI suggests that the a, b, b ,a n da   domains form a
twisted U shape with the catalytic domains facing each
other and an internal hydrophobic surface that interacts
with substrate proteins [23]. Residues 101–144 of mature
PDIhavesigniﬁcantsimilarity(29.5%identity)withresidues
350–392 of ERα. Moreover, residues 163–211 of mature PDI
are homologous with residues 304–349 of ERα.I ti sn o t e -
worthy that PDI segment 101–144 comprises the C-terminal
part of the a domain, a short interdomain linker, and N-
terminal part of the b domain, whereas segment 163–211 is
exclusively located in the b domain. It would seem plausible
that estrogen binding may cause a conformational change
that interferes with the functional coordination between
the catalytic domain and substrate-binding region, with
the consequence that PDI enzymatic activity is suppressed.
Accordingly, the apparent Kd value of PDI for estrogens
such as β-estradiol has been determined to be 1.5–2μM
[10]. The catalytic activity of PDI (measured by insulin
degradation or reactivation of randomly oxidized RNase) is
inhibited by estradiol in vitro,w i t ha nI C 50 of approximately
100nM [21]. As an estrogen-binding protein, PDI can
serve to modulate the intracellular estrogen reservoir and
slow down estrogen metabolic disposition. Moreover, under
certain conditions, PDI-bound estrogen can be released and
augment the transcriptional activity of ERα [10].
S-Glutathionylation of proteins generally occurs on cys-
teineresidueswithalowpKa[3].Usingsite-directedmutage-
nesis we generated a mutant PDI that is S-glutathionylation
refractory with isomerase activity equivalent to native PDI.
Transfection of PDI-FLFL into breast cancer cells resulted
in diminished PABA/NO-induced toxicity as a result of
S-glutathionylation refractory PDI. Hence the triggers for
abolishing the ERα-PDI complex and activation of the UPR
were blunted.
Our present data indicate that PDI is an ERα-interacting
partner. Previously, studies have been designed to determine
whether PDI regulates ERα protein levels. RNAi technology
has been used to knock down PDI in MCF-7 cells but
interpretation of results has not always been consistent.
For example, Fu et al. demonstrated that PDI knockdown
is associated with downregulation of ERα [10], whereas
Schultz-Norton et al. reported the exact opposite ﬁnding
that decreased expression of PDI leads to an increase in
ERα protein levels [13]. Both groups have used at least
two diﬀerent RNAi sequences, thus a precise understanding
of the relationship between PDI and ERα stability remains8 International Journal of Cell Biology
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anti-PDI antibodies. (f) MCF7 cells transfected with control ()o rP D I - F L F L( ) were seeded in a 96-well plate and treated with 0–25μM
PABA/NO. Cell viability was measured at 72h with the MTT assay [14]. Data represent the mean for 3 independent experiments ± S.D.International Journal of Cell Biology 9
undeﬁned. The results from the present study demonstrate
that PDI levels do have a direct impact on ERα stabil-
ity. Moreover, changes in redox homeostasis induced by
nitrosative/oxidative stress cause S-glutathionylation of PDI
and mediate cell death through activation of the UPR and
abrogation of ERα stability and signaling.
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